New Innovative Active Ingredient

Bringing a new AI through the regulatory system has certainly been a learning experience for our team, but one that should serve us well as we strive to launch several more AIs in the next five years.

The experience also provides an opportunity to reflect on the effectiveness of the PMRA relative to other market regulators. In the case of BREVIS™, while the EU and US did approve earlier than the PMRA, we can still point to our regulatory environment as a reason to invest in Canada.

We appreciate that competing pressures from industry and other stakeholder groups make it difficult to find the right balance, but in our experience the process registering BREVIS™ is generally transparent and science based. 

Of course, we do have a healthy list of areas we’d like to see improved and we look forward to our new government following through on their commitment to ensure efficient and predictable regulations across the industry.